Relieves bronchospasm. ANDA 218386, held by The Ritedose. Albuterol Sulfate.
As of Nov 18, 2026, ANDA 218386 (Albuterol Sulfate), held by The Ritedose, was first approved by FDA on Mar 12, 2025, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Albuterol inhalation solution is indicated for the relief of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 12, 2025 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Albuterol SulfateEQ 0.5% BASE · solution;inhalation | Albuterol Sulfate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters